Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) Inc on Monday, setting a price target of $35, which is approximately 78.66% above the present share price of $19.59.
M. Kusy expects Iovance Biotherapeutics Inc to post earnings per share (EPS) of -$0.55 for the fourth quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Iovance Biotherapeutics, with an average price target of $34.43.
The analysts price targets range from a high of $50 to a low of $20.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$86.24 million. The company's market cap is $3.07 billion.
According to TipRanks.com, Robert W. Baird analyst Colleen M. Kusy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.3% and a 32.35% success rate.
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.